nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—CYP2D6—Methimazole—Graves' disease	0.236	0.611	CbGbCtD
Galantamine—CYP3A4—Methimazole—Graves' disease	0.15	0.389	CbGbCtD
Galantamine—CHRNE—pituitary gland—Graves' disease	0.0367	0.14	CbGeAlD
Galantamine—CHRNA5—eye—Graves' disease	0.0345	0.132	CbGeAlD
Galantamine—CHRNA5—thyroid gland—Graves' disease	0.0221	0.0846	CbGeAlD
Galantamine—CHRNG—adipose tissue—Graves' disease	0.0182	0.0698	CbGeAlD
Galantamine—CHRNA3—eye—Graves' disease	0.0146	0.0558	CbGeAlD
Galantamine—CHRNB1—eye—Graves' disease	0.0126	0.0483	CbGeAlD
Galantamine—CHRND—thyroid gland—Graves' disease	0.0125	0.0479	CbGeAlD
Galantamine—CHRNB2—pituitary gland—Graves' disease	0.0112	0.0427	CbGeAlD
Galantamine—CHRNB2—adipose tissue—Graves' disease	0.0111	0.0425	CbGeAlD
Galantamine—CHRNA1—thyroid gland—Graves' disease	0.0105	0.04	CbGeAlD
Galantamine—CHRNB2—thyroid gland—Graves' disease	0.00962	0.0368	CbGeAlD
Galantamine—CHRNA7—eye—Graves' disease	0.00953	0.0365	CbGeAlD
Galantamine—CHRNA9—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00952	0.0477	CbGpPWpGaD
Galantamine—CHRNB1—adipose tissue—Graves' disease	0.00933	0.0357	CbGeAlD
Galantamine—CHRNA2—thyroid gland—Graves' disease	0.00868	0.0332	CbGeAlD
Galantamine—CHRNB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00832	0.0417	CbGpPWpGaD
Galantamine—CHRNB1—thyroid gland—Graves' disease	0.00807	0.0309	CbGeAlD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00789	0.0395	CbGpPWpGaD
Galantamine—Neuropathy peripheral—Methimazole—Graves' disease	0.00776	0.0505	CcSEcCtD
Galantamine—CHRFAM7A—thyroid gland—Graves' disease	0.00755	0.0289	CbGeAlD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00753	0.0377	CbGpPWpGaD
Galantamine—CHRNA9—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00716	0.0359	CbGpPWpGaD
Galantamine—Hepatitis—Methimazole—Graves' disease	0.0071	0.0463	CcSEcCtD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00708	0.0355	CbGpPWpGaD
Galantamine—ACHE—thyroid gland—Graves' disease	0.007	0.0268	CbGeAlD
Galantamine—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00659	0.0429	CcSEcCtD
Galantamine—CHRNB3—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00626	0.0314	CbGpPWpGaD
Galantamine—CHRNA7—thyroid gland—Graves' disease	0.0061	0.0233	CbGeAlD
Galantamine—Haemoglobin—Propylthiouracil—Graves' disease	0.00607	0.0395	CcSEcCtD
Galantamine—Haemorrhage—Propylthiouracil—Graves' disease	0.00604	0.0393	CcSEcCtD
Galantamine—Hepatitis—Propylthiouracil—Graves' disease	0.00604	0.0393	CcSEcCtD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00598	0.03	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00593	0.0297	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00566	0.0284	CbGpPWpGaD
Galantamine—Vertigo—Methimazole—Graves' disease	0.00555	0.0362	CcSEcCtD
Galantamine—CHRNA9—Neuronal System—GABRA3—Graves' disease	0.00549	0.0275	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00532	0.0267	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00526	0.0264	CbGpPWpGaD
Galantamine—Arthralgia—Methimazole—Graves' disease	0.00526	0.0343	CcSEcCtD
Galantamine—Myalgia—Methimazole—Graves' disease	0.00526	0.0343	CcSEcCtD
Galantamine—Dysgeusia—Propylthiouracil—Graves' disease	0.00515	0.0335	CcSEcCtD
Galantamine—Thrombocytopenia—Methimazole—Graves' disease	0.00494	0.0322	CcSEcCtD
Galantamine—CHRNB3—Neuronal System—GABRA3—Graves' disease	0.00479	0.024	CbGpPWpGaD
Galantamine—Vertigo—Propylthiouracil—Graves' disease	0.00472	0.0308	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Methimazole—Graves' disease	0.0046	0.0299	CcSEcCtD
Galantamine—CHRNA5—Neuronal System—GABRA3—Graves' disease	0.00455	0.0228	CbGpPWpGaD
Galantamine—Paraesthesia—Methimazole—Graves' disease	0.00453	0.0295	CcSEcCtD
Galantamine—CHRNA6—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.0045	0.0225	CbGpPWpGaD
Galantamine—Somnolence—Methimazole—Graves' disease	0.00449	0.0292	CcSEcCtD
Galantamine—Arthralgia—Propylthiouracil—Graves' disease	0.00448	0.0291	CcSEcCtD
Galantamine—Myalgia—Propylthiouracil—Graves' disease	0.00448	0.0291	CcSEcCtD
Galantamine—Dyspepsia—Methimazole—Graves' disease	0.00444	0.0289	CcSEcCtD
Galantamine—CHRNG—Neuronal System—GABRA3—Graves' disease	0.00434	0.0217	CbGpPWpGaD
Galantamine—Thrombocytopenia—Propylthiouracil—Graves' disease	0.0042	0.0274	CcSEcCtD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00419	0.021	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00415	0.0208	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—GABRA3—Graves' disease	0.00408	0.0204	CbGpPWpGaD
Galantamine—BCHE—pituitary gland—Graves' disease	0.00399	0.0153	CbGeAlD
Galantamine—Body temperature increased—Methimazole—Graves' disease	0.00399	0.026	CcSEcCtD
Galantamine—BCHE—adipose tissue—Graves' disease	0.00397	0.0152	CbGeAlD
Galantamine—CHRNB2—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00396	0.0198	CbGpPWpGaD
Galantamine—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00391	0.0255	CcSEcCtD
Galantamine—Paraesthesia—Propylthiouracil—Graves' disease	0.00385	0.0251	CcSEcCtD
Galantamine—Somnolence—Propylthiouracil—Graves' disease	0.00381	0.0248	CcSEcCtD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00379	0.019	CbGpPWpGaD
Galantamine—Dyspepsia—Propylthiouracil—Graves' disease	0.00378	0.0246	CcSEcCtD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.0036	0.018	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00356	0.0178	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—GABRA3—Graves' disease	0.00344	0.0173	CbGpPWpGaD
Galantamine—BCHE—thyroid gland—Graves' disease	0.00344	0.0132	CbGeAlD
Galantamine—Body temperature increased—Propylthiouracil—Graves' disease	0.00339	0.0221	CcSEcCtD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00338	0.017	CbGpPWpGaD
Galantamine—Vomiting—Methimazole—Graves' disease	0.00321	0.0209	CcSEcCtD
Galantamine—Rash—Methimazole—Graves' disease	0.00318	0.0207	CcSEcCtD
Galantamine—Dermatitis—Methimazole—Graves' disease	0.00318	0.0207	CcSEcCtD
Galantamine—Headache—Methimazole—Graves' disease	0.00316	0.0206	CcSEcCtD
Galantamine—CHRND—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00315	0.0158	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00312	0.0156	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—GABRA3—Graves' disease	0.00303	0.0152	CbGpPWpGaD
Galantamine—Nausea—Methimazole—Graves' disease	0.003	0.0195	CcSEcCtD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00293	0.0147	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00285	0.0143	CbGpPWpGaD
Galantamine—Vomiting—Propylthiouracil—Graves' disease	0.00273	0.0178	CcSEcCtD
Galantamine—Rash—Propylthiouracil—Graves' disease	0.00271	0.0176	CcSEcCtD
Galantamine—CHRNA7—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.0027	0.0136	CbGpPWpGaD
Galantamine—Dermatitis—Propylthiouracil—Graves' disease	0.0027	0.0176	CcSEcCtD
Galantamine—Headache—Propylthiouracil—Graves' disease	0.00269	0.0175	CcSEcCtD
Galantamine—CHRNA1—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00268	0.0134	CbGpPWpGaD
Galantamine—Nausea—Propylthiouracil—Graves' disease	0.00255	0.0166	CcSEcCtD
Galantamine—CHRNA2—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00254	0.0127	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—GABRA3—Graves' disease	0.00241	0.0121	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—GABRA3—Graves' disease	0.00239	0.012	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.0022	0.011	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—GABRA3—Graves' disease	0.00218	0.0109	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—GABRA3—Graves' disease	0.00207	0.0104	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—GABRA3—Graves' disease	0.00205	0.0103	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—GABRA3—Graves' disease	0.00195	0.00976	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—GABRA3—Graves' disease	0.00169	0.00847	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00157	0.00788	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.0014	0.00703	CbGpPWpGaD
Galantamine—ACHE—Monoamine Transport—IL1B—Graves' disease	0.00134	0.0067	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—FAS—Graves' disease	0.00132	0.00663	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—GABRA3—Graves' disease	0.00121	0.00604	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—GABRA3—Graves' disease	0.00108	0.00539	CbGpPWpGaD
Galantamine—ACHE—Monoamine Transport—TNF—Graves' disease	0.000971	0.00486	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000948	0.00475	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—IFNG—Graves' disease	0.000919	0.00461	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000746	0.00374	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000733	0.00367	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000688	0.00345	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000654	0.00328	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000648	0.00325	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000568	0.00285	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000548	0.00274	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000542	0.00271	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000528	0.00265	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—B3GNT2—Graves' disease	0.00048	0.00241	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—TNF—Graves' disease	0.00047	0.00236	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—B3GNT2—Graves' disease	0.000428	0.00215	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000383	0.00192	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GC—Graves' disease	0.000326	0.00164	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GC—Graves' disease	0.000291	0.00146	CbGpPWpGaD
Galantamine—ACHE—Metabolism—B3GNT2—Graves' disease	0.000247	0.00124	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000232	0.00117	CbGpPWpGaD
Galantamine—BCHE—Metabolism—B3GNT2—Graves' disease	0.000221	0.00111	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GC—Graves' disease	0.000134	0.000671	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—B3GNT2—Graves' disease	0.000101	0.000509	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GC—Graves' disease	8.75e-05	0.000439	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—B3GNT2—Graves' disease	6.63e-05	0.000332	CbGpPWpGaD
